Overview

• GSK will receive a $370 million payment from CureVac after resolving their US mRNA vaccine patent dispute.
• CureVac has granted BioNTech and Pfizer rights to produce, use, and sell mRNA-based Covid-19 and flu vaccines under the settlement.
• GSK is eligible for an additional $130 million if BioNTech completes its acquisition of CureVac, settling related litigation outside the United States.
• The British drugmaker continues to pursue separate patent infringement cases against Pfizer and BioNTech in both the US and Europe.
• Shares in GSK rose by as much as 1.7% on the news of the settlement and licensing agreement.